# Fujian Shengdi Pharmaceutical Co., Ltd. trials: 66 (2026)

ClinicalTrials.gov lists 66 trials with Fujian Shengdi Pharmaceutical Co., Ltd. as lead sponsor, 21 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Fujian Shengdi Pharmaceutical Co., Ltd.: 66 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/fujian-shengdi-pharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 66
- Recruiting or not yet: 21
- Read on: November 19, 2026

## Trials

The 25 newest of 66, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 28, 2026 | NCT07843862 | A Study of HRS-4729 Injection in Participants With Type 2 Diabetes | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Type 2 Diabetes | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843862) |
| September 25, 2026 | NCT07841860 | A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-1596 Tablets in Healthy Participants With a Single Dose... | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Weight Management, Type 2 Diabetes | 122 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07841860) |
| September 8, 2026 | NCT07807059 | A Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Overweight/Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH), Type 2... | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807059) |
| September 3, 2026 | NCT07802964 | A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of HRS-4139 in Healthy... | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Psoriasis Vulgaris | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07802964) |
| September 2, 2026 | NCT07799688 | A Extension Study to Evaluate the Safety and Efficacy of HRS-7249 in Patients With Hypertriglyceridemia | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Hyperlipidemia | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07799688) |
| July 17, 2026 | NCT07709910 | A Trial of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Participants With Obesity and Knee Osteoarthritis | 382 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07709910) |
| July 17, 2026 | NCT07709897 | A Clinical Trial of HRS5580 for Injection Combined With Palonosetron Hydrochloride for the Prevention of Postoperative Nausea and Vomiting | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Prevention of Postoperative Nausea and Vomiting | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07709897) |
| July 8, 2026 | NCT07690826 | A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Overweight or Obesity | 252 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07690826) |
| July 2, 2026 | NCT07681479 | A Mass Balance Study of \[14C\]HRS-9057 for Injection in Healthy Participants | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 1 | Active not recruiting | Fluid Retention Due to Heart Failure | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07681479) |
| June 26, 2026 | NCT07670884 | A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Chronic Management of Body Weight | 675 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07670884) |
| June 22, 2026 | NCT07660848 | A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated Steatohepatitis | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Metabolic Dysfunction-Associated Steatohepatitis (MASH) | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07660848) |
| May 26, 2026 | NCT07606950 | Phase III Study of HRS-5635 in Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B | 540 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07606950) |
| May 20, 2026 | NCT07599410 | A Research Study to Investigate the Efficacy and Safety of HRS9531 Tablets in Participants With Type 2 Diabetes Mellitus | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | T2DM | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07599410) |
| April 30, 2026 | NCT07559136 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 Injection in Adolescents With Obesity | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 1 | Active not recruiting | Overweight and Obesity | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07559136) |
| April 24, 2026 | NCT07551492 | A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Atherosclerotic Cardiovascular Disease | 9,262 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551492) |
| April 20, 2026 | NCT07540754 | A Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Diabetes Mellitus, Weight Loss | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07540754) |
| January 5, 2026 | NCT07318103 | Phase II Clinical Study of HRS-9057 Injection in Patients With Heart Failure-induced Fluid Retention | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Fluid Retention Caused by Heart Failure | 153 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07318103) |
| December 29, 2025 | NCT07308392 | Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High... | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 2 | Active not recruiting | Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis | 119 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07308392) |
| December 22, 2025 | NCT07297797 | Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 2 | Active not recruiting | Mild to Moderate Hypertension | 238 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07297797) |
| December 16, 2025 | NCT07285902 | A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 3 | Active not recruiting | Obesity | 572 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07285902) |
| November 18, 2025 | NCT07233070 | HRS-7450 Injection Phase II Clinical Trial for Acute Ischemic Stroke. | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 2 | Completed | Acute Ischemic Stroke | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07233070) |
| September 26, 2025 | NCT07195604 | A Single Ascending Dose of HRS-2162 in Healthy Subjects | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 1 | Completed | Reversal of Neuromuscular Blockade | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07195604) |
| September 22, 2025 | NCT07185776 | A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 2 | Active not recruiting | Lipoprotein Disorder | 203 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07185776) |
| September 2, 2025 | NCT07150962 | Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Overweight or Obesity | 168 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07150962) |
| August 12, 2025 | NCT07117474 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-9563 in Subjects With Mild... | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 1 | Completed | Subjects With Mild Hypertension | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07117474) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 29 |
| Phase 2 | 23 |
| Phase 3 | 14 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 31 |
| Recruiting | 16 |
| Active not recruiting | 9 |
| Unknown | 5 |
| Not yet recruiting | 5 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Diabetes Mellitus, Type 2 | 16 |
| Obesity | 13 |
| Overweight | 11 |
| Hyperlipidemias | 3 |
| Ischemic Stroke | 2 |
| Hepatitis B, Chronic | 2 |
| Weight Loss | 2 |
| Vomiting | 1 |
| Dyslipidemias | 1 |
| Atherosclerosis | 1 |
| Sleep Apnea, Obstructive | 1 |
| Hyperphagia | 1 |
| Fatty Liver | 1 |
| Stroke | 1 |
| Nausea | 1 |
| Diabetes Mellitus | 1 |
| Osteoarthritis, Knee | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Laser cutting companies in the United States](https://specstream.ai/data/businesses/laser-cutting-companies/united-states)
- [Whiskey bars in the United States](https://specstream.ai/data/businesses/whiskey-bars/united-states)
- [Furniture wholesalers in the United States](https://specstream.ai/data/businesses/furniture-wholesalers/united-states)
- [Smoothie and juice bars in the United States](https://specstream.ai/data/businesses/smoothie-and-juice-bars/united-states)
- [Debt relief companies in the United States](https://specstream.ai/data/businesses/debt-relief-companies/united-states)
